FimmCyte is developing disease modifying therapies for chronic diseases through the direct elimination of diseased cells. FimmCyte has a pipeline of assets two of which are about to begin IND enabling studies, one for endometriosis and the second for organ fibrosis.
Member of the Swiss Biotech Association
Member
Fimmcyte AG
